EN | UA
EN | UA

Help Support

Back

Nepafenac single drop proves sufficient for IVI related pain management

Nepafenac single drop proves sufficient for IVI related pain management Nepafenac single drop proves sufficient for IVI related pain management
Nepafenac single drop proves sufficient for IVI related pain management Nepafenac single drop proves sufficient for IVI related pain management

What's new?

Nepefenac 0.3% exhibits potent analgesic effect in reducing pain and improving quality of life of  patients with more intense pain perception.

A recent study based on a randomised clinical trial published in 'Journal of Ocular Pharmacology and Therapeutics' revealed that a single instillation of nepafenac 0.1% or 0.3% before intravitreal injections (IVI) could effectively alleviate the pain concerning IVI.

Constantine D. Georgakopoulos and colleagues examined the analgesic effect of nepafenac 0.3% in patients undergoing IVI of antivascular endothelial growth factors. The patients were randomized into three Groups in this single-centre, prospective, randomized, blinded, triple-arm, placebo-controlled interventional study. In the 1st Group total, 33 patients received nepafenac 0.1%, in the 2nd  Group total, 32 patients received nepafenac 0.3%, and in the 3rd Group total 31 patients received placebo 40 min before IVI. The short form of the McGill Pain Questionnaire (SF-MPQ), pain intensity was assessed with the visual analog scale (VAS), Main Component of the SF-MPQ and present pain intensity (PPI) scores were used immediately and at 6 hours after the injection.It was found that the VAS pain score was statistically significantly lower in patients treated with nepafenac 0.1% and 0.3% as compared to placebo immediately after IVI. When nepafenac 0.1% or 0.3% was instilled, the PPI scores were statistically significantly lower as compared to placebo. After nepafenac, 0.1% and 0.3% administration, the main component of the SF-MPQ scores were statistically significantly lower as compared to placebo. Six hours after the IVI, nepafenac 0.3% exhibited statistically significantly higher analgesic effect as compared to nepafenac 0.1% and placebo as this was indicated by the VAS pain score and PPI score."The 0.3% nepafenac formula exerts its analgesic effect more thoroughly at 6 hours after the IVI", noted Constantine D. Georgakopoulos et al.

Source:

Journal of Ocular Pharmacology and Therapeutics

Article:

Analgesic Effect of a Single Drop of Nepafenac 0.3% on Pain Associated with Intravitreal Injections: A Randomized Clinical Trial

Authors:

Constantine D. Georgakopoulos et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: